BR0211601A - Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos - Google Patents

Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos

Info

Publication number
BR0211601A
BR0211601A BR0211601-4A BR0211601A BR0211601A BR 0211601 A BR0211601 A BR 0211601A BR 0211601 A BR0211601 A BR 0211601A BR 0211601 A BR0211601 A BR 0211601A
Authority
BR
Brazil
Prior art keywords
preparing
technical process
flibanserine
stable polymorph
drug preparation
Prior art date
Application number
BR0211601-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Carlo Bombarda
Enrica Dubini
Antoine Ezhaya
Original Assignee
Bidachem Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem Spa filed Critical Bidachem Spa
Publication of BR0211601A publication Critical patent/BR0211601A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR0211601-4A 2001-08-02 2002-07-30 Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos BR0211601A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19
PCT/EP2002/008466 WO2003014079A1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Publications (1)

Publication Number Publication Date
BR0211601A true BR0211601A (pt) 2004-08-24

Family

ID=26076670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211601-4A BR0211601A (pt) 2001-08-02 2002-07-30 Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos

Country Status (26)

Country Link
EP (2) EP1414816B1 (cg-RX-API-DMAC7.html)
JP (1) JP3822601B2 (cg-RX-API-DMAC7.html)
KR (1) KR100899297B1 (cg-RX-API-DMAC7.html)
CN (1) CN1288147C (cg-RX-API-DMAC7.html)
AR (2) AR036208A1 (cg-RX-API-DMAC7.html)
AT (1) ATE288911T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002331361B2 (cg-RX-API-DMAC7.html)
BR (1) BR0211601A (cg-RX-API-DMAC7.html)
CA (1) CA2450093C (cg-RX-API-DMAC7.html)
CO (1) CO5560572A2 (cg-RX-API-DMAC7.html)
DE (1) DE60202958T2 (cg-RX-API-DMAC7.html)
DK (1) DK1414816T3 (cg-RX-API-DMAC7.html)
EA (1) EA006400B1 (cg-RX-API-DMAC7.html)
ES (1) ES2237694T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20040107B1 (cg-RX-API-DMAC7.html)
HU (1) HU228666B1 (cg-RX-API-DMAC7.html)
IL (2) IL159151A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000913A (cg-RX-API-DMAC7.html)
MY (1) MY127294A (cg-RX-API-DMAC7.html)
NZ (1) NZ530510A (cg-RX-API-DMAC7.html)
PL (1) PL210224B1 (cg-RX-API-DMAC7.html)
PT (1) PT1414816E (cg-RX-API-DMAC7.html)
RS (1) RS50742B (cg-RX-API-DMAC7.html)
SI (1) SI1414816T1 (cg-RX-API-DMAC7.html)
UA (1) UA76767C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003014079A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA80135C2 (en) * 2002-05-22 2007-08-27 Boehringer Ingelheim Pharma Pharmaceutical composition containing flibanserin polymorph a
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007099070A1 (en) * 2006-02-28 2007-09-07 Boehringer Ingelheim International Gmbh Treatment of prevention of valvular heart disease with flibanserin
RS54398B1 (sr) * 2006-05-09 2016-04-28 Sprout Pharmaceuticals, Inc. Upotreba flibanserina za lečenje poremećaja seksualne želje u postmenopauzi
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
CA2672957C (en) 2006-12-20 2015-04-14 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN108699007A (zh) * 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
JP2004537597A (ja) 2004-12-16
HU228666B1 (en) 2013-05-28
ES2237694T3 (es) 2005-08-01
EA200400252A1 (ru) 2004-08-26
PL210224B1 (pl) 2011-12-30
CA2450093A1 (en) 2003-02-20
HRP20040107B1 (hr) 2012-02-29
MY127294A (en) 2006-11-30
JP3822601B2 (ja) 2006-09-20
HK1070063A1 (en) 2005-06-10
EA006400B1 (ru) 2005-12-29
DK1414816T3 (da) 2005-04-11
EP1414816B1 (en) 2005-02-09
HUP0401201A2 (hu) 2004-10-28
NZ530510A (en) 2004-07-30
DE60202958D1 (de) 2005-03-17
AU2002331361B2 (en) 2008-06-05
PT1414816E (pt) 2005-04-29
CA2450093C (en) 2008-09-23
IL159151A (en) 2009-09-22
KR20040023704A (ko) 2004-03-18
CN1288147C (zh) 2006-12-06
AR036208A1 (es) 2004-08-18
HRP20040107A2 (en) 2004-06-30
AR077416A2 (es) 2011-08-24
WO2003014079A8 (en) 2003-11-20
DE60202958T2 (de) 2006-04-06
PL364598A1 (en) 2004-12-13
CN1551879A (zh) 2004-12-01
RS50742B (sr) 2010-08-31
IL159151A0 (en) 2004-06-01
HUP0401201A3 (en) 2004-11-29
WO2003014079A1 (en) 2003-02-20
CO5560572A2 (es) 2005-09-30
EP1518858A1 (en) 2005-03-30
SI1414816T1 (en) 2005-06-30
KR100899297B1 (ko) 2009-05-26
UA76767C2 (uk) 2006-09-15
MXPA04000913A (es) 2004-10-27
YU7804A (sh) 2006-08-17
ATE288911T1 (de) 2005-02-15
EP1414816A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
BR0211601A (pt) Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
HK1046527A1 (zh) 金剛烷衍生物
BR0007980A (pt) Processo para a preparação de derivadosmulti-reticulados de ácido hialurÈnico, hamulti-reticulado, ha reticulado em si próprio,produto, e, uso de ha
BR0014827A (pt) Derivados de terc-butil-(7-metil-imidazo (1,2-a) piridin-3-il) amina, procedimento de sua preparação, medicamentos que os contém, sua utilização para a preparação de medicamento para inibição de no-sintase e composições farmacêuticas que os contém
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
BR0015048A (pt) Sal farmacêutico, medicamento, uso de pelo menos um sal de tramadol e formas de apresentação
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0209845A (pt) Formas de dosagem de oxcarbazepina e processo para a preparação das mesmas
NO20035450D0 (no) Antranilsyreamider med en heteroarylsulfonyl sidekjede, fremgangsmåte for fremstilling derav, anvendelse som et legemiddel eller diagnostiske-og farmas degree ytiske preparater som inneholder nevnte forbindelser
MY123193A (en) Novel 2-(iminomethyl)amino-phenyl derivatives,preparation,application as medicines and compositions containing same
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
AR009741A1 (es) Nuevos derivados de la benzamidina, procedimiento para prepararlos, preparados farmaceuticos que los contienen y su empleo como medicamentos.
PT1165081E (pt) Processo para a preparacao de preparacoes farmaceuticas cintendo tolperisona, para administracao oral
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
BRPI0208468B8 (pt) camsilato de amlodipina e processo para sua preparação
BR0211063A (pt) Sais de derivados anticonvulsivantes
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
BRPI0416188A (pt) formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2003018535A3 (en) Novel aminobenzoephenones

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SPROUT PHARMACEUTICALS, INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.